|
1
|
Enzinger PC and Mayer RJ: Esophageal
cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zeng H, Zheng R, Zhang S, Zuo T, Xia C,
Zou X and Chen W: Esophageal cancer statistics in China, 2011:
Estimates based on 177 cancer registries. Thorac Cancer. 7:232–237.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Napier KJ, Scheerer M and Misra S:
Esophageal cancer: A review of epidemiology, pathogenesis, staging
workup and treatment modalities. World J Gastrointest Oncol.
6:112–120. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lagergren J and Lagergren P: Recent
developments in esophageal adenocarcinoma. CA Cancer J Clin.
63:232–248. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sohda M and Kuwano H: Current status and
future prospects for esophageal cancer treatment. Ann Thorac
Cardiovasc Surg. 23:1–11. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gebski V, Burmeister B, Smithers BM, Foo
K, Zalcberg J and Simes J; Australasian Gastro-Intestinal Trials
Group, : Survival benefits from neoadjuvant chemoradiotherapy or
chemotherapy in oesophageal carcinoma: A meta-analysis. Lancet
Oncol. 8:226–234. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Tepper J, Krasna MJ, Niedzwiecki D, Hollis
D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D and Mayer
R: Phase Iii trial of trimodality therapy with cisplatin,
fluorouracil, radiotherapy, and surgery compared with surgery alone
for esophageal cancer: CALGB 9781. J Clin Oncol. 26:1086–1092.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kamta J, Chaar M, Ande A, Altomare DA and
Ait-Oudhia S: Advancing cancer therapy with present and emerging
immuno-oncology approaches. Front Oncol. 7:642017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Doi T, Piha-Paul SA, Jalal SI, Mai-Dang H,
Yuan S, Koshiji M, Csiki I and Bennouna J: Pembrolizumab (Mk-3475)
for patients (Pts) with advanced esophageal carcinoma: Preliminary
results from keynote-028. J Clin Oncol. 33:2015.
|
|
10
|
Kudo T, Hamamoto Y, Kato K, Ura T, Kojima
T, Tsushima T, Hironaka S, Hara H, Satoh T, Iwasa S, et al:
Nivolumab treatment for oesophageal squamous-cell carcinoma: An
open-label, multicentre, phase 2 trial. Lancet Oncol. 18:631–639.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He
Q, Chen T, Roszik J, Bernatchez C, Woodman SE, et al: Loss of IFN-γ
pathway genes in tumor cells as a mechanism of resistance to
anti-CTLA-4 therapy. Cell. 167:397–404.e9. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
De Henau O, Rausch M, Winkler D, Campesato
LF, Liu C, Cymerman DH, Budhu S, Ghosh A, Pink M, Tchaicha J, et
al: Overcoming resistance to checkpoint blockade therapy by
targeting PI3Kγ in myeloid cells. Nature. 539:443–447. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zaretsky JM, Garcia-Diaz A, Shin DS,
Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY,
Abril-Rodriguez G, Sandoval S, Barthly L, et al: Mutations
associated with acquired resistance to PD-1 blockade in melanoma. N
Engl J Med. 375:819–829. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Barclay AN and Van den Berg TK: The
interaction between signal regulatory protein alpha (SIRPα) and
Cd47: Structure, function, and therapeutic target. Annu Rev
Immunol. 32:25–50. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Matozaki T, Murata Y, Okazawa H and
Ohnishi H: Functions and molecular mechanisms of the CD47-SIRPα
signalling pathway. Trends Cell Biol. 19:72–80. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Baccelli I, Stenzinger A, Vogel V,
Pfitzner BM, Klein C, Wallwiener M, Scharpff M, Saini M,
Holland-Letz T, Sinn HP, et al: Co-expression of MET and CD47 is a
novel prognosticator for survival of luminal breast cancer
patients. Oncotarget. 5:8147–8160. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chan KS, Espinosa I, Chao M, Wong D,
Ailles L, Diehn M, Gill H, Presti J Jr, Chang HY, van de Rijn M, et
al: Identification, molecular characterization, clinical prognosis,
and therapeutic targeting of human bladder tumor-initiating cells.
Proc Natl Acad Sci USA. 106:pp. 14016–14021. 2009; View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tseng D, Volkmer JP, Willingham SB,
Contreras-Trujillo H, Fathman JW, Fernhoff NB, Seita J, Inlay MA,
Weiskopf K, Miyanishi M and Weissman IL: Anti-CD47
antibody-mediated phagocytosis of cancer by macrophages primes an
effective antitumor T-cell response. Proc Natl Acad Sci USA.
110:pp. 11103–11108. 2013; View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhao XW, van Beek EM, Schornagel K, van
der Maaden H, Van Houdt M, Otten MA, Finetti P, Van Egmond M,
Matozaki T, Kraal G, et al: CD47-signal regulatory protein-α
(SIRPα) interactions form a barrier for antibody-mediated tumor
cell destruction. Proc Natl Acad Sci USA. 108:pp. 18342–18347.
2011; View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Willingham SB, Volkmer JP, Gentles AJ,
Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin
R, Cohen JD, et al: The CD47-signal regulatory protein α (SIRPα)
interaction is a therapeutic target for human solid tumors. Proc
Natl Acad Sci USA. 109:pp. 6662–6667. 2012; View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu X, Pu Y, Cron K, Deng L, Kline J,
Frazier WA, Xu H, Peng H, Fu YX and Xu MM: CD47 blockade triggers T
cell-mediated destruction of immunogenic tumors. Nat Med.
21:1209–1215. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chao MP, Alizadeh AA, Tang C, Myklebust
JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, et al:
Anti-CD47 antibody synergizes with rituximab to promote
phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 142:699–713.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Majeti R, Chao MP, Alizadeh AA, Pang WW,
Jaiswal S, Gibbs KD Jr, van Rooijen N and Weissman IL: CD47 is an
adverse prognostic factor and therapeutic antibody target on human
acute myeloid leukemia stem cells. Cell. 138:286–299. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chao MP, Majeti R and Weissman IL:
Programmed cell removal: A new obstacle in the road to developing
cancer. Nat Rev Cancer. 12:58–67. 2011.PubMed/NCBI
|
|
25
|
Allum WH, Bonavina L, Cassivi SD, Cuesta
MA, Dong ZM, Felix VN, Figueredo E, Gatenby PA, Haverkamp L, Ibraev
MA, et al: Surgical treatments for esophageal cancers. Ann N Y Acad
Sci. 1325:242–268. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chistiakov DA, Killingsworth MC,
Myasoedova VA, Orekhov AN and Bobryshev YV: CD68/macrosialin: Not
just a histochemical marker. Lab Invest. 97:4–13. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chao MP, Weissman IL and Majeti R: The
CD47-SIRPα pathway in cancer immune evasion and potential
therapeutic implications. Curr Opin Immunol. 24:225–232. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Oldenborg PA, Zheleznyak A, Fang YF,
Lagenaur CF, Gresham HD and Lindberg FP: Role of Cd47 as a marker
of self on red blood cells. Science. 288:2051–2054. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Barclay AN: Signal regulatory protein
alpha (SIRPalpha)/Cd47 interaction and function. Curr Opin Immunol.
21:47–52. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu X, Kwon H, Li Z and Fu YX: Is Cd47 an
innate immune checkpoint for tumor evasion? J Hematol Oncol.
10:122017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tao H, Qian P, Wang F, Yu H and Guo Y:
Targeting CD47 enhances the efficacy of anti-PD-1 and CTLA-4 in
esophageal squamous cell cancer preclinical model. Oncol Res. Mar
23–2017. View Article : Google Scholar
|
|
34
|
Suzuki S, Yokobori T, Tanaka N, Sakai M,
Sano A, Inose T, Sohda M, Nakajima M, Miyazaki T, Kato H, et al:
CD47 expression regulated by the miR-133a tumor suppressor is a
novel prognostic marker in esophageal squamous cell carcinoma.
Oncol Rep. 28:465–472. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yang C, Gao S, Zhang H, Xu L, Liu J, Wang
M and Zhang S: CD47 is a potential target for the treatment of
laryngeal squamous cell carcinoma. Cell Physiol Biochem.
40:126–136. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yuan A, Hsiao YJ, Chen HY, Chen HW, Ho CC,
Chen YY, Liu YC, Hong TH, Yu SL, Chen JJ, et al: Opposite effects
of M1 and M2 macrophage subtypes on lung cancer progression. Sci
Rep. 5:142732015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhang M, Hutter G, Kahn SA, Azad TD,
Gholamin S, Xu CY, Liu J, Achrol AS, Richard C, Sommerkamp P, et
al: Anti-CD47 treatment stimulates phagocytosis of glioblastoma by
M1 and M2 polarized macrophages and promotes M1 polarized
macrophages in vivo. PLoS One. 11:e01535502016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Weiskopf K, Jahchan NS, Schnorr PJ,
Cristea S, Ring AM, Maute RL, Volkmer AK, Volkmer JP, Liu J, Lim
JS, et al: CD47-blocking immunotherapies stimulate
macrophage-mediated destruction of small-cell lung cancer. J Clin
Invest. 126:2610–2620. 2016. View
Article : Google Scholar : PubMed/NCBI
|
